News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Osiris Therapeutics, Inc. (OSIR) Expands Its Grafix® Product Portfolio And Launches Additional Sizes


7/17/2014 11:10:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced the addition of several new sizes to the Grafix® product line. Grafix, a cryopreserved placental membrane, is regulated under 21 CFR 1271, part 361, Human Cells, Tissues and Cellular Tissue-Products (HCT/Ps) as a wound cover. Like other HCT/Ps, Grafix can be manufactured in multiple sizes, giving health care providers the ability to optimally match Grafix to the wound size, reduce overall treatment costs and eliminate concerns regarding product waste. Grafix is now available in five convenient sizes and is very well-positioned to remain a cost effective option within the Centers for Medicare & Medicaid Services bundled payment system.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES